Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer

  • Kim, Byoung Hyuck (Department of Radiation Oncology, Seoul National University Bundang Hospital) ;
  • Eom, Keun-Yong (Department of Radiation Oncology, Seoul National University Bundang Hospital) ;
  • Kim, Jae-Sung (Department of Radiation Oncology, Seoul National University Bundang Hospital) ;
  • Kim, Hyung-Ho (Department of General Surgery, Seoul National University Bundang Hospital) ;
  • Park, Do Joong (Department of General Surgery, Seoul National University Bundang Hospital)
  • Received : 2013.06.24
  • Accepted : 2013.08.13
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the role of salvage radiotherapy (RT) for the treatment of regional lymph node recurrence (RLNR) after radical surgery in advanced gastric cancer. Materials and Methods: We retrospectively analyzed medical records of 26 patients who underwent salvage treatment after diagnosis of RLNR between 2006 and 2011. Patients with peritoneal seeding or distant metastasis were excluded. Eighteen patients received RT with or without chemotherapy and the other 8 did chemotherapy only without RT. A three-dimensional conformal RT was performed with median dose of 56 Gy (range, 44 to 60 Gy). Sixteen patients had fluoropyrimidine-based chemotherapy, 5 did taxane-based chemotherapy, and irinotecan was applied in 4. Results: With a median follow-up of 20 months (range, 5 to 57 months), median overall survival (OS) and progression-free survival (PFS) after diagnosis of RLNR were 29 months and 12 months in the entire patients, respectively. Radiotherapy (p = 0.007) and disease-free interval (p = 0.033) were statistically significant factors for OS in multivariate analysis. Median OS was 36 months in patients who received RT and 16 months in those who did not. Furthermore, delivery of RT (p < 0.001), complete remission after salvage treatment (p = 0.040) and performance status (p = 0.023) were associated with a significantly better PFS. Gastrointestinal toxicities from RT were mild in most patients. Conclusion: Salvage RT combined with systemic chemotherapy may be an effective treatment managing RLNR from advanced gastric cancer.

Keywords

References

  1. Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2009. Seoul: Ministry of Health and Welfare; 2011.
  2. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012;44:11-24. https://doi.org/10.4143/crt.2012.44.1.11
  3. Saito H, Fukumoto Y, Osaki T, et al. Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. Ann Surg Oncol 2007;14:1688-93. https://doi.org/10.1245/s10434-006-9314-3
  4. Chang JS, Lim JS, Noh SH, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol 2012;104:367-73. https://doi.org/10.1016/j.radonc.2012.08.017
  5. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002;9:394-400. https://doi.org/10.1007/BF02573875
  6. Li JH, Zhang SW, Liu J, Shao MZ, Chen L. Review of clinical investigation on recurrence of gastric cancer following curative resection. Chin Med J (Engl) 2012;125:1479-95.
  7. Song KY, Park SM, Kim SN, Park CH. The role of surgery in the treatment of recurrent gastric cancer. Am J Surg 2008;196:19-22. https://doi.org/10.1016/j.amjsurg.2007.05.056
  8. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30. https://doi.org/10.1056/NEJMoa010187
  9. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma (2nd English edition). Gastric Cancer 1998;1:10-24. https://doi.org/10.1007/PL00011681
  10. Ha TK, Kwon SJ. Clinicopathological characteristics for type of recurrence in gastric cancer patients. J Korean Gastric Cancer Assoc 2007;7:23-30.
  11. Eom BW, Yoon H, Ryu KW, et al. Predictors of timing and patterns of recurrence after curative resection for gastric cancer. Dig Surg 2010;27:481-6. https://doi.org/10.1159/000320691
  12. Sun J, Sun YH, Zeng ZC, et al. Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer. Int J Radiat Oncol Biol Phys 2010;77:384-91. https://doi.org/10.1016/j.ijrobp.2009.05.019
  13. Koizumi W, Nakayama N, Tanabe S, et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 2012;69: 407-13. https://doi.org/10.1007/s00280-011-1701-1
  14. Choi YH, Oh SC, Kim JS, et al. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group protocol ST06-02. Cancer Chemother Pharmacol 2012;70:665-72. https://doi.org/10.1007/s00280-012-1956-1
  15. Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci 2009;24:488-92. https://doi.org/10.3346/jkms.2009.24.3.488
  16. Takemura N, Saiura A, Koga R, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012;397:951-7. https://doi.org/10.1007/s00423-012-0959-z
  17. Makino H, Kunisaki C, Izumisawa Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res 2010;30:2367-76.
  18. Tsujimoto H, Ichikura T, Ono S, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 2010;4:406-13. https://doi.org/10.1007/s12072-009-9161-y
  19. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol 2012;30:3507-15. https://doi.org/10.1200/JCO.2011.35.8028
  20. Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012;84:e585-92. https://doi.org/10.1016/j.ijrobp.2012.07.2378
  21. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-73. https://doi.org/10.1200/JCO.2011.39.1953
  22. Lee DJ, Sohn TS, Lim DH, et al. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol 2012;69:1333-8. https://doi.org/10.1007/s00280-012-1836-8

Cited by

  1. Effects of High-Intensity Focused Ultrasound for Treatment of Abdominal Lymph Node Metastasis From Gastric Cancer vol.34, pp.3, 2013, https://doi.org/10.7863/ultra.34.3.435
  2. A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer vol.97, pp.23, 2013, https://doi.org/10.1097/md.0000000000010786
  3. Radiotherapy Combined with Chemotherapy for Regional Lymph Node Recurrence in Gastric Cancer vol.12, pp.None, 2013, https://doi.org/10.2147/cmar.s280225